Home / Transcripts / Neurocrine Biosciences, Inc. (NBIX) · May 5, 2026

Neurocrine Biosciences, Inc. (NBIX) Earnings Call Transcript

May 5, 2026

NASDAQ US Health Care Biotechnology earnings 57 min

Earnings Call Speaker Segments

Todd Tushla executive
#1

Thanks, and happy Cinco de Mayo, everybody. You're listening to Neurocrine Biosciences' 1st quarter 2026 earnings call. On the line with me today: Kyle Gano, our Chief Executive Officer; Matthew Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; Sanjay Keswani, Chief Medical Officer; and Samir Siddhanti, Vice President of Strategy and Corporate Development. We'll be sharing forward-looking statements on this call, among them projections about future events, including the expected closing of the Soleno Therapeutics acquisition we plan to make; such statements carry certain risks and uncertainties, and what actually happens could differ materially. Please take a look at the risk factors covered in our most recent SEC filings. Also, a portion of what we discuss today consists of Non-GAAP financial measures, which were not calculated in accordance with U.S. GAAP. You'll find reconciliations of those Non-GAAP financial measures to the most directly comparable GAAP financial measures in the tables at the back of the earnings release we issued earlier today, which is now up on the investor relations page of the company's website. Once our prepared remarks wrap up, we'll take your questions. So with that, I'll pass things over to Kyle.

Kyle Gano executive
#2

Appreciate that, Todd. Afternoon, everybody. For a number of years now, we've laid out a distinct vision: turning into a top-tier biopharmaceutical firm powered by expanding and diversifying the revenue we generate, all while pushing our pipeline forward and broadening it. The results from quarter one show real movement down that road. Quarterly net product sales crossed $800 million for the very first time in Neurocrine's history — that's 44% growth compared with the same period a year ago. INGREZZA drove the bulk of these excellent numbers, and it's now in year 9 post-launch, still expanding at a double-digit pace. With INGREZZA's guidance kept at $2.7 billion-$2.8 billion, CRENESSITY now running at an annualized rate above $600 million, plus VYKAT XR set to join our commercial lineup once the deal closes, we're in a strong spot to post record net product sales in 2026. On the topic of VYKAT XR and the planned purchase of Soleno Therapeutics, the tender offer still being underway means we won't be able to say much in response to questions today. Closing is still expected during quarter two. Even so, the Soleno team has really impressed us — strong clinical outcomes in a complicated disease, broad usage made possible through a simple label, and a solid launch for VYKAT XR. We can't wait to officially bring them into the Neurocrine family soon. Going forward, our shared focus stays on a smooth integration, with one aim: helping patients in the United States who live with Prader-Willi syndrome. Past beefing up our commercial offerings, we keep funding our R&D operation in neurology, psychiatry, endocrinology, and immunology. Evidence of pipeline momentum: we intend to launch 6 fresh phase I and phase II programs during this year by itself. During 2027, important data readouts will come for osavampator in Major Depressive Disorder, direclidine in schizophrenia, and NBIP-2118 in obesity — those are just a handful of examples. Add up the staying power and continued growth potential of our commercial products, our inventive R&D operation, and our improving financial picture, and Neurocrine sits in a one-of-a-kind position to create lasting value for patients and shareholders alike. Company-wide momentum has never been higher, and we've only just begun. With that, I'll hand things over to Matt.

Matthew Abernethy executive
#3

Thanks, Kyle, and good afternoon, everyone. To begin, I want to congratulate our commercial and medical teams on a fantastic quarter. Total revenue came in above $800 million, representing growth of more than 40% compared with the prior year. What's important is that for both INGREZZA and CRENESSITY, this result speaks to robust underlying demand and the real difference we are making in patients' lives. Starting with INGREZZA, sales in the first quarter of 2026 reached $657 million, a 20% increase year-over-year, fueled by volume growth in the double digits and record numbers of new patients. After accounting for the fact that Q1 2025 had one fewer order week, growth came to roughly 11%. We're pleased with how strong the business looks coming out of Q1, and we are reaffirming our 2026 guidance for INGREZZA of $2.7 billion-$2.8 billion. In line with how we've done things historically, we'll revisit that guidance after the first half of the year. Now to CRENESSITY: sales in the first quarter of 2026 totaled $153 million, powered by solid persistency and new patient enrollment forms that held steady versus Q4. Broad prescriber adoption and favorable reimbursement dynamics remain evident. As we expected, Q1 brought some slight gross to net pressure stemming from commercial co-pay resets. Looking forward, we stay very encouraged by what we're seeing and continue to believe CRENESSITY is well-positioned to become a blockbuster medicine. Our revenue performance keeps supporting R&D investment while profitability expands. In the first quarter, we produced roughly $200 million of net income on a GAAP and Non-GAAP basis, respectively, which reflects strong operating execution. On a GAAP basis, these results included gains related to equity investments and the sale of the Diurnal business. On a Non-GAAP basis, these results include $44 million in milestone expense into IPR&D. As you model operating expenses for the remainder of the year, the full impact of the commercial expansion will show up beginning in the second quarter. Stepping back, INGREZZA and CRENESSITY together form a growing commercial foundation, generating durable cash flows that allow continued investment in innovation and strategic business development opportunities. That aligns directly with our capital allocation priorities: number 1, drive revenue growth; number 2, advance our pipeline; and 3, invest in business development. On the announced acquisition of Soleno and VYKAT XR, we're excited to bring this asset into our portfolio and bolster our long-term growth profile; we aren't providing financial guidance tied to the transaction right now and will keep our commentary limited during Q&A. Assuming a second quarter close, we expect to share additional financial details on our Q2 earnings call. All told, the first quarter shows strong momentum across both our commercial portfolio and pipeline, with multiple key data readouts anticipated over the next 18 months, including osavampator, direclidine, and our CRF2 obesity program. With that, I'll hand the call over to Eric Benevich, our Chief Commercial Officer. Eric?

Eric Benevich executive
#4

Thanks, Matt. On May 1st, we hit nine years since INGREZZA first became available. It's pretty striking that nine years after the FDA gave its approval and we launched, we're still posting record figures for new patients starting treatment. That says a lot about how well our commercial team has executed and about how much unmet need exists among people living with tardive dyskinesia. The money we keep putting into our sales force, into marketing efforts such as DTC, and into better formulary access is plainly producing strong results. I'd like to recognize our commercial and medical colleagues, who keep making a real difference for patients by easing the burden of tardive dyskinesia or chorea tied to Huntington's disease. We're proud of what we've achieved, but what excites us even more is how much opportunity is still out there. Of the roughly 800,000 TD patients estimated in the U.S., about 90% aren't getting first-line standard of care today with a VMAT2 inhibitor such as INGREZZA. As antipsychotic use keeps climbing quickly, tardive dyskinesia prevalence should grow over time faster than the U.S. population increases; and with a larger pool of psychiatric healthcare providers for our recently expanded sales force to call on, we expect those tailwinds to drive robust demand and sales through this year's back half. Before finishing my remarks on INGREZZA, let me remind everyone that May is Mental Health Awareness Month, and this particular week is Tardive Dyskinesia Awareness Week, which around here we fondly call TDAW. Each year we mark this week on our calendar, working alongside leading patient advocacy groups in mental health, plus state and local governments nationwide, to build awareness and bring hope to the many thousands of people who suffer from TD unnecessarily. Turning back to CRENESSITY, the powerful momentum from 2025, our first year of commercial launch, continued into how we performed in Q1 2026. The CRENESSITY launch keeps going extremely well, with consistent new patient starts, strong persistency and compliance rates, and favorable reimbursement, in line with what we saw during the fourth quarter of 2025. Importantly, trial and adoption are expanding across every prescriber segment, among them CAH Centers of Excellence, pediatric endocrinologists, and community adult endocrinologists. During Q1, more than 1,200 healthcare providers have written prescriptions for CRENESSITY. Adoption stays balanced between pediatric and adult populations and between female and male patients, with a modest continuing skew toward pediatrics and females, matching earlier trends. As Sanjay will cover in greater detail, we keep producing compelling long-term efficacy, safety, and tolerability data, which further strengthens the value proposition and CRENESSITY's emerging role as a standard of care treatment alongside low-dose GCs for classic CAH patients. With sales now annualizing above $600 million, CRENESSITY is well on its way to reaching blockbuster status. With that, I'll hand the call to Dr. Sanjay Keswani, our Chief Medical Officer, who will discuss progress across our exciting clinical pipeline.

Sanjay Keswani executive
#5

Thank you, Eric. Hello, everyone, and good afternoon. Two scientific conferences that took place recently are where I want to start, with their key highlights. The first was the 2026 annual meeting of the American Association of Clinical Endocrinology, held in Las Vegas. There, we shared new results from the 2-year CRENESSITY phase IIi cahtalyst adult study, which showed substantial and sustained decreases in glucocorticoid doses among adults who have classic congenital adrenal hyperplasia. Roughly 70% of patients reached glucocorticoid doses falling inside the physiological range while androgen control stayed intact. In fact, an equivalent share of patients — that is, 70% — durably attained normal androgen levels. Based on those two-year results, CRENESSITY achieved lasting androgen suppression while also enabling substantial reductions in glucocorticoid use. This in turn produced favorable outcomes related to bone health, bone aging, hirsutism, acne, weight, and insulin resistance. Notably, these gains remained stable as time went on, with more than 80% of participants staying in the study and no new safety or tolerability concerns emerging. All of this supports positioning CRENESSITY as a long-term therapeutic choice that represents a significant advance in care for patients with classic CAH. We're eager to share more 2-year data covering a wider range of clinical endpoints and outcomes at future medical meetings, including ENDO 2026 in June. Back in April, at the 2026 annual meeting of the Academy of Managed Care Pharmacy, we shared the first real-world head-to-head claims data pitting INGREZZA against deuterated tetrabenazine. Those findings demonstrated better treatment persistence for INGREZZA capsules, including greater long-term continuation rates and fewer medication switches among adults living with tardive dyskinesia. Notably, this stronger persistence with INGREZZA emerged early on in treatment and remained consistent throughout a 6-month follow-up window. Since this is the first head-to-head comparison of its type, the results provide important evidence that can guide clinical practice decisions and further support how differentiated INGREZZA is. Now, regarding our clinical portfolio, the priority for this year is to build and move the pipeline forward; every one of our phase II studies is enrolling at present. Among them is NBI-890, our next-generation VMAT2 follow-on for tardive dyskinesia. Also included is direclidine, a selective M4 muscarinic agonist we are developing for bipolar mania. Then there's NBI-'570, our selective dual M1 and M4 muscarinic agonist for schizophrenia. A phase II study will evaluate crinecerfont in classic CAH patients younger than 4 years old. We expect to launch that study within the next few months. Also, right now we've got nine phase I programs in motion altogether. One of them is NBIP-2118 — that's a peptide agonist targeting the corticotropin-releasing factor type 2 receptor, being developed for obesity — and we expect top-line results from it in 2027. Then in 2026, we intend to kick off four more phase I trials. Those include NBIP-1968, which is our own triple G agonist, tested alongside NBIP-2118 for obesity. There's also NBIB-223, a gene therapy we're developing for Friedreich's ataxia, plus NBI-188, our CRF1 antagonist aimed at a women's health indication. With all that pipeline momentum heading into 2026, Neurocrine is set up for a number of significant data catalysts: phase IIi results for osavampator in Major Depressive Disorder, a phase IIi trial of direclidine in schizophrenia, and a phase IIi study readout we anticipate the following year. In closing, our 2026 efforts are focused on advancing a broad and varied pipeline, which sets us up to generate substantial clinical and commercial value beginning in 2027. During our R&D day this past December in 2025, we noted that this marks just the beginning. Kyle, I'll now hand things back to you.

Kyle Gano executive
#6

Thanks, Sanjay. Nikki, I think we're ready for questions now.

Tazeen Ahmad analyst
#7

Hey, everyone. I appreciate you taking my question. Nice work on a solid quarter. I'd like to ask about how CRENESSITY is growing. Compared with your expectations for this point in time, how is that launch going? Could you tell us about the efforts to activate physicians? Are they bringing back patients who are older, and at the moment where do the majority of their scripts originate? Thanks.

Kyle Gano executive
#8

Thank you, Tazeen. I'll have Eric handle that one.

Eric Benevich executive
#9

Hello Tazeen. On the whole, I'd say we've moved ahead of our expectations for this stage — roughly 5 quarters in since launch. We're definitely quite happy with the uptake that carried on through Q1. New patient starts, I'd call them quite stable and in line with what Q4 showed us, plus persistency and compliance remain strong, and reimbursement has been favorable. Because of that, both prescriptions and sales are building up well. One thing I'll note, however: for most physicians who've written a prescription for CRENESSITY, the count of patients treated so far sits at just 1. Despite the strong strides made during the launch's first year, the bulk of patients still haven't received treatment; we see a considerable opportunity in front of us.

Tazeen Ahmad analyst
#10

Thanks.

Paul Matteis analyst
#11

Great. Thanks so much. Let me add my congratulations on a great quarter. Regarding INGREZZA and CRENESSITY, could you verify there were no significant inventory build changes or other one-time items that might have given a temporary lift to the results for this 1Q. As a second part to this for INGREZZA, in earlier years there have been some nuanced seasonality factors and headwinds in 1Q that, you know, have caused you temporary problems in January and February, but in the end produce some tailwinds into 2Q. I was curious if you could address what that seasonality pattern may have looked like this quarter. Has it improved now that you've contracted? As a result, like, what might the sequential cadence look like this year compared to prior years? Thank you.

Matthew Abernethy executive
#12

Yeah. As for inventory, nothing was material, nothing worth noting. A truly clean quarter reflecting very strong underlying demand. The team did a really good job managing through seasonality this quarter and would expect it to be somewhat similar to what you've seen historically. Well done to the team and we're set up for a nice growth year, the rest of 2026.

Brian Abrahams analyst
#13

Hello there, good afternoon. I appreciate you taking my question, and congratulations from me too on such a solid quarter. Regarding CRENESSITY, from what I gather, the forms for new patient starts have been coming in at a steady, consistent pace. I was hoping you might expand a bit further on that, and perhaps share what the proper approach would be for us to think about the anticipated cadence ahead, simply drawing on the patterns you have been seeing recently? Thank you.

Kyle Gano executive
#14

Thanks, Brian. Kyle here. I believe Eric did a good job describing the situation with new patient starts in Q1. Like we said before, we're shifting away from giving out specific figures and instead concentrating more on top line net sales going forward, which aligns with what other businesses that wear orphan medicines do. Embracing that approach and offering detail wherever we feel it matters; regarding Q1, we observed solid, consistent new patient starts from Q4 into Q1, and that carried over into persistency and consistency or compliance too, plus a continued favorable reimbursement rate of dispense scripts. Because of that, there's been a wide buildup of patients over time since launch, and that's what has driven our strong Q1 results, and we're eager to build on it with our expanded sales team for the rest of the year.

Cory Kasimov analyst
#15

Okay, thank you. I’m grateful you took my question. Yes, it was a strong quarter, though I’d like to shift direction somewhat and ask about the pipeline. I’m wondering whether you can share anything regarding the accrual-stage phase IIi neuropsych assets—so that’s both MDD and schizophrenia—and when you expect you may be better able to give more detailed or narrower guidance on the timing of those top line readouts, which could perhaps draw somewhat more attention there. Thank you.

Kyle Gano executive
#16

Thanks. I appreciate the question. I think I'll let Sanjay take this.

Sanjay Keswani executive
#17

When it comes to the phase IIi programs — particularly osavampator for MDD and direclidine in schizophrenia — enrollment is going quite nicely across all of them. The rate at which we're enrolling right now makes us very pleased. In fact, phase IIi studies ought to produce readouts in the coming year. Turning to direclidine, we'll be at phase IIi the year after that. All of it is proceeding as initially planned.

Cory Kasimov analyst
#18

All right. Thanks very much.

Corinne Johnson analyst
#19

Thank you. Good afternoon, everyone. I'm wondering whether you might spend a moment discussing the reauthorization activities that occurred for CRENESSITY during Q1, and whether you could offer any observations regarding reimbursement patterns among that group. Thanks.

Eric Benevich executive
#20

Hello. Just to remind everyone, the classic CAH patient group beginning CRENESSITY looks fairly distinct from what we observe with tardive dyskinesia when viewed through a payer lens. Within the CAH population, commercial insurance is the leading category, with Medicaid coming in as the second largest segment; we aren't seeing a spike in reauthorizations as a new calendar year begins the way we do with INGREZZA, given the limited Medicare exposure. What typically happens is that once a patient receives authorization for a first prescription, that approval generally lasts either 6 months or 12 months; after that, reauthorizations take place when that original batch of prescriptions exhausts its authorized fills. On the whole, the rate of reauthorization approvals has been really high, matching what we observed with initial approvals for CRENESSITY, and things are progressing quite well.

Phil Nadeau analyst
#21

Good afternoon. Please let me also say congrats on a strong quarter. I'd like to build on what you told Tazeen when answering her. From what I recall, during that response you mentioned that the overwhelming majority of doctors had written a prescription for CRENESSITY just one time; we'd love a bit more granularity regarding where the patients who are starting are originating, whether that's community or expert centers. What our own checks indicate is that a fair share of patients have been arriving from expert centers. Should we expect that to keep going? Do you think you've started to max out that portion of the market and are shifting further into community, or does a substantial amount of additional room remain at the expert centers? Thanks.

Eric Benevich executive
#22

Yeah, to put it briefly, no part of this market has been saturated by us yet. The commercial ramp for CRENESSITY is still in its early days. As a reminder, when you consider the three prescriber segments that exist, the CAH Centers of Excellence, the pediatric endocrinologists and the adult community endocrinologists. What we estimated was that roughly 15-ish% of patients right now are being cared for by one of those CAH Centers of Excellence. Broadly speaking, when it comes to how the business has been distributed thus far, it has been proportional with respect to, you know, where business is coming from. At the end of the day, we understand that the biggest factor limiting how quickly patients get started is probably how patients move through these practices. For most of these patients, they visit their physician just once per year when they're an adult patient. When the patient is pediatric, that could be two or three times per year. You know, I believe that plays a role in this extremely consistent pace of new patient additions. Of course, since we're early in the launch, a number of these physicians are gaining their first experience, and should they have more patients, they are simply waiting for those patients to come through. I think expanding the sales force will truly let us boost not just the depth of prescribing, but also the breadth of the prescriber base.

Phil Nadeau analyst
#23

That's quite useful. Thanks.

Brian Skorney analyst
#24

Hello, good afternoon, everybody. Appreciate you taking my question. Wonderful quarter. It appears that, you know, we have grown fairly used to it, and the street appears skilled at projecting the kinds of first quarter headlines that INGREZZA encounters. You've discussed, you know, a considerably different payer mix for CRENESSITY, but I'm simply curious whether you might provide some color or perhaps even quantification regarding any seasonality you're observing there. In other words, or should we instead view this as a sort of step up going forward that would land somewhere around the $20 million per quarter range?

Eric Benevich executive
#25

Hey, Brian, one clarification. Are you directing that remark toward INGREZZA or toward what to expect for CRENESSITY seasonality?

Brian Skorney analyst
#26

No — what are you noticing, if anything, when it comes to seasonality for CRENESSITY? I believe that, you know, at this point the street has a pretty solid grasp of how seasonality works for INGREZZA.

Eric Benevich executive
#27

Yeah.

Brian Skorney analyst
#28

I just want to ask — you know, could you help us get a sense of whatever you might be observing for CRENESSITY?

Eric Benevich executive
#29

Sure. When it comes to gross-to-net, perhaps a few points of gain relative to Q1. Broadly speaking, we remain quite early in this launch cycle, so pinning down a typical seasonality pattern isn't something we could confidently do. What we do know, as Eric mentioned before, is that patient flow stays fairly steady from one quarter to the next, simply because the prescriber universe is so limited. I wouldn't say there are huge seasonal swings of the kind you Maybe not huge, but seasonal patterns similar to what INGREZZA shows.

Matthew Abernethy executive
#30

Yeah. No. I'll just add something here.

Eric Benevich executive
#31

Oh, my apologies. I'll simply add to that and mention that, you know, in Q1 we don't experience the bolus of reauthorizations that we see with INGREZZA. For CRENESSITY, the commercial ramp remains at an early stage, and we're gaining considerable insight into patient dynamics and, sort of, those ebbs and flows. I think what has really stood out as the overlying theme is just how consistent adoption has been across the community. Clearly, with the sales force expansion, we'll be in a position to, you know, go deeper with the existing prescriber base and also broaden that base over time.

Brian Skorney analyst
#32

All right, excellent; that helps. I appreciate it.

Anupam Rama analyst
#33

Hi, everyone. We really appreciate you fielding the question, and congratulations on the quarter. I just have a brief question regarding the ENDO meeting that's coming up. What key market efforts—physician outreach types of initiatives, I suppose—will you be running at the conference? And give us a refresher on any data updates related to CRENESSITY that we might anticipate at that meeting. Many thanks.

Eric Benevich executive
#34

Anupam, I'll take the first portion of what you asked. As you can imagine, we're eager for ENDO to arrive in June, since it gives us a chance to connect with the wider endocrinology community; as a matter of fact, we recently attended a few significant endocrinology gatherings within just the last few weeks; over this past weekend, the Pediatric Endocrine Society meeting took place in your area, in San Francisco, and I attended and was truly struck by what I'd describe as the energy and enthusiasm shown by pediatric endos who had worked with CRENESSITY. That meeting featured 2 separate seminars focused on CAH, and both drew packed rooms, which I believe signals how much interest there is. We had numerous KOL engagements there, so we definitely left with considerable momentum. We anticipate carrying similar momentum away from the June ENDO meeting.

Sanjay Keswani executive
#35

Sure, I'll take the second portion of that question, Anupam. My sense is that the community has stayed enthusiastic about the 2-year open label data we've presented, which demonstrates the effect of lower glucocorticoid doses along with reduced androgen levels; that ties to improved weight management, less insulin resistance, and fewer virilization problems, such as less acne and slower bone age advancement, which clearly matters enormously when it comes to children reaching their adult heights; all of this comes with genuinely strong safety and tolerability; we've reached 35,000 patient week exposures at this point. Overall, I'm quite thrilled by how the community has responded, whether at recent Endo conferences or at upcoming ones later this year.

Jay Olson analyst
#36

Oh, hi there, congratulations on everything you've accomplished, and thanks for giving us this update. You're intending to bring your Friedreich's ataxia gene therapy program into the clinic during this year, so could you describe the design of the phase I study and what kind of initial data we ought to anticipate in 2027? On a separate note, regarding your NLRP3 program that was licensed recently, perhaps you could discuss the timeline for advancing that into the clinic and how that molecule aligns with your core therapeutic areas. Thank you.

Kyle Gano executive
#37

Yeah. Jay, it's Kyle here. I appreciate the question. I believe I'll concentrate only on the Friedreich's ataxia program, and the two of us can connect offline regarding the other programs in the portfolio. We expect to launch the FA program soon. As soon as every detail of that gets settled, you'll find it posted on clinicaltrials.gov. At that point, we can discuss it further. Our intention is to share patient-level data near the end of next year. You can think of this as a phase I-b trial; dosing will begin in the patient population. We're thrilled about the possibility of providing curative therapy to patients, and I'm eager to say more on this later in the year, especially at R&D Day, where we'll be able to walk through the program in greater depth.

Jay Olson analyst
#38

Thank you.

Myles Minter analyst
#39

Thanks to each of you for fielding the question. Nice work on the quarter. I just wanted to hear your latest perspective on the triple G agonist you have. Of course, Lilly's TRANSCEND type 2 diabetes data is out, and it's fairly striking, though it did reveal quite elevated rates of vomiting, diarrhea, and nausea. Given that you're still planning to combine this with a CRF2 agonist, I'm curious what your refreshed view is on the therapeutic window, especially as you move that into phase I development during this year. Thanks.

Sanjay Keswani executive
#40

I appreciate the question, Myles Minter. For us, it's still early days. Obviously, we're going to be quite enthusiastic about the readout for our CRF2 agonist for obesity, as you noted, which is coming next year. We're working on the assumption that it will serve as our core constituent across a number of different combinations, among them one involving the Triple G program. For our Triple G program, first-in-human is what we're aiming at this year; we'll be able to potentially examine clinical data iteratively from both programs to figure out the optimal combination as it relates to the risk/benefit profile.

Analyst analyst
#41

This is Hoyle filling in for Ash. We appreciate you answering our question. Looking at INGREZZA from a payer coverage angle, VYKAT XR recently dropped preferred status with a handful of major plans; we were hoping to get a sense of what that means for INGREZZA through the remainder of this year and into next year. Could it be that PBMs are shifting commercial coverage ahead of the IRA year as a way to protect their rebates? Thank you.

Kyle Gano executive
#42

Perhaps I'll address this one. When it comes to 2026, our coverage looks a lot like how we finished 2025. Roughly 70% of all TD and HD Medicare beneficiary lives have INGREZZA coverage, which leaves us well positioned regarding the loss of deuterated tetrabenazine on certain plans. On a relative basis, I think, for things approved for INGREZZA, we wouldn't anticipate any broad shifts when it comes to INGREZZA reimbursement.

Basma Radwan operator
#43

Hello, this is Basma filling in for Marc. We appreciate you addressing our inquiry. Following up on what was asked previously regarding the 24-month results for CRENESSITY, might you again clarify the prevalence of insulin resistance and obesity within the pediatric CAH population, plus adults? What was the response from physicians to these findings, and what level of clinical significance did they attribute to them? Regarding persistency, that too has remained quite robust up to now. Could you repeat what the primary factors are behind patients stopping CRENESSITY? That concludes our questions. Many thanks.

Sanjay Keswani executive
#44

Regarding the first portion of your question. Sadly, it's fairly typical for kids with CAH to put on extra pounds and to struggle with insulin resistance along with other cardiometabolic problems. A major reason for this is the large amounts of glucocorticoids these patients are given. Another suspected factor in this cardiometabolic sickness burden is the elevated androgen levels they usually have. As for CRENESSITY, the effects observed in the 2-year data have gotten a very positive response from the community, who consider those effects clinically meaningful. Eric, over to you for part two.

Eric Benevich executive
#45

Right, so I really want to highlight that in the real-world setting, we've observed very strong persistence and compliance with CRENESSITY, which lines up with what we saw in our phase III trials. As a reminder, in both the adult and pediatric studies, roughly 95% of patients finished those trials and rolled over. And in the 2-year open label data that we've recently been presenting at conferences, more than 80% of patients completed 2 years. It's been quite favorable when it comes to patients staying on treatment, and I think that's a major factor behind the buildup in prescriptions and sales that we're seeing this early in the launch.

Sanjay Keswani executive
#46

That's a fair point.

Basma Radwan analyst
#47

Thanks.

Analyst analyst
#48

Hello, Susan here, filling in for Mohit. Great results this quarter — congratulations. We have 2 things to ask. First, regarding CRENESSITY. Forgive me if this was covered already, but were you able to put a figure on new patient starts as opposed to persistent patients? Should a specific answer not be possible, then at a broad level, what does that picture look like? Second, a pipeline follow-up: when it comes to schizophrenia and MDD, what positioning do you anticipate for those drugs? Thanks.

Eric Benevich executive
#49

The first portion of your question is mine to address. No, a specific count of new patient starts wasn't provided by us. Our statement was that during Q1, the pace of new patient additions held very steady, and that pattern aligned closely with Q4 of the prior year.

Sanjay Keswani executive
#50

Okay, regarding the second portion of what you asked. It's worth noting that the patients in our ongoing phase IIi trials are individuals who haven't responded well to an antidepressant. Usually it's an antidepressant that hasn't produced a good response, and what we're basically doing is adding on top of that antidepressant in order to get a superior response; that's potentially the niche we could fill in the market too. Obviously, we're also examining other lifecycle opportunities for this molecule.

Poorna Kannan analyst
#51

Hello, Poorna Kannan here, filling in for Ami Fadia. Thanks for taking our question, and congratulations on the strong quarter. Regarding CRENESSITY, you mentioned before that you've reached roughly 10% of the addressable market, with demand strongest in pediatric, then adult females, then adult males. How do you expect those patterns to develop over this year? And for NBIP-2118, what would the phase I data need to show to justify moving forward with development? Thank you.

Eric Benevich executive
#52

We aren't yet at a stage where we can provide guidance on CRENESSITY. What I can tell you is that we're still in the early part of the commercial ramp, and we're gaining a great deal of insight into this patient population and this prescriber base; we saw, I should say, a very steady and consistent rate of new patient adds in Q1. Thanks to the sales force expansion, we anticipate being able to build depth within that prescriber base, while also continuing to bring on new prescribers. Many of these patients, too, are not being cared for by an endocrinologist. Through our patient-finding efforts, we expect to be able to reach and activate some of those patients during this year as well. We feel very good about where we stand with the CRENESSITY launch, and there's certainly plenty of room for organic growth ahead.

Sanjay Keswani executive
#53

Regarding NBIP-2118, that trial is only now beginning to get underway, and results from it should be available during the latter portion of 2027.

Poorna Kannan analyst
#54

Understood. I appreciate it.

David Amsellem analyst
#55

Thank you. I'd like to hear more detail on NBIP-01435, since you have phase II results coming in CAH next year. Could you address how its potency stacks up against CRENESSITY at the CRF1 receptor? And beyond that, what would you require seeing on the differentiation front relative to CRENESSITY — on clinical outcomes as well as biomarker outcomes — before you'd justify pushing it further? Thanks.

Sanjay Keswani executive
#56

Yes; our NBIP-01435 program has us quite enthusiastic. For background, what we have here is an injectable peptide. The advantage is that dosing for patients could happen at infrequent intervals. Also, we hold encouraging data, at least from preclinical work, showing more durable efficacy, and that ties to how long the efficacy lasts along with how deep that efficacy goes. A benefit from the perspective of drug development is that strong biomarkers exist in the CAH space. We're able to put the biomarker readouts head-to-head, androgen reduction included, with the phase II program against what we saw previously with CRENESSITY.

Eric Benevich executive
#57

Perhaps I could add a little more on that point. You referred to it as our R&D day. For our endocrine franchise, in connection with conditions involving HPA axis dysregulation, we laid out a strategy built in tiers. As you know, CRENESSITY will serve as the foundational therapy within that approach for many years ahead. That one can be regarded as first line, while NBIP-01435 gives patients a different route of administration and potentially other forms of differentiation that we will be able to determine through the clinical program. That one can be viewed as second line.

Kyle Gano executive
#58

This is one piece of a broader set of initiatives that, in our view, could reach various groups of patients, for those with CAH going forward.

Yigal Nochomovitz analyst
#59

Yes. Hello. Thank you. Congratulations on the impressive quarter too. I wanted to ask about the 90% of TD patients who aren't taking a VMAT2 inhibitor right now. Given the latest consensus guidance on screening for TD in long-term care, how much could that potentially boost the share gains within that 90% portion of the TD population?

Eric Benevich executive
#60

Yes. It will definitely be beneficial. What we've observed as time has passed is that, partly because of the work we've done to educate people, awareness of tardive dyskinesia has grown, and routine screening for tardive dyskinesia has become something we see more often and more regularly in various care settings, with long-term care included more lately. When there are established criteria and agreement on why screening matters and how to carry it out, particularly for people living in long-term care facilities, I believe that heightens the level of suspicion in nursing homes, and we're able to assist a greater number of individuals. Another point I want to emphasize is that May is Mental Health Awareness Month, and this particular week is TD Awareness Week. Our field teams, sales teams, and medical teams are absolutely using TD Awareness Week to amplify the enthusiasm and momentum behind TD screening in every care setting, long-term care among them.

Yigal Nochomovitz analyst
#61

All right, thank you. Just one brief question regarding CRENESSITY and the pediatric extension for those patients under—

Kyle Gano executive
#62

Hi, go ahead Yigal, I’ll get back to you following the call. Thank you.

Sumant Kulkarni analyst
#63

Thanks; this comes in two parts. How do you view the possibility of creating CRF antagonists for cognition and working memory re-related conditions? At present you have numerous pipeline programs aimed at a number of therapeutic areas. Are any of them already designated for outside partnering, contingent on how they advance through the pipeline?

Kyle Gano executive
#64

Yeah. Matt, Kyle here. I'll address your second question, the one about partnering. What we're aiming for at this moment is to keep advancing programs within our main therapeutic areas: neurology, psychiatry, endocrinology, and immunology. At this point, I'd say our pipeline leans more heavily toward psychiatry, but as our R&D engine pushes additional programs into the clinic, you'll see that shift into other modalities — small molecules, proteins, peptides — along with therapies spanning disease modification and symptomatic treatment of disease. We'll pursue the science into these various therapeutic areas, since we now possess expertise across them. Currently, nothing is slated for partnering, but as time goes on and we observe how these programs advance, we'd certainly find ourselves in a position to weigh those kinds of relationships going forward. That isn't something unfamiliar to us. As you're aware, Neurocrine was built on partnerships, both in and out licensing.

Sanjay Keswani executive
#65

On that first question, that's a genuinely fascinating idea. In fact, based only on what we've seen anecdotally among those we treat for CAH, we've documented gains in executive functioning, which hints that a connection to CRF and cognition could exist. That is plainly a research area for us, and I'm confident we'll be putting out some data about it later on.

Sumant Kulkarni analyst
#66

Thanks.

Yatin Suneja analyst
#67

Just a fast question for Matt. Could you perhaps walk me through the tax situation? My understanding is that the prior year came in around 30% for the full year. What's the right way for us to think about modeling it for this year, and then perhaps over the longer term? Thanks.

Matthew Abernethy executive
#68

Oh, tax questions are always a favorite of mine. No, for this year I'd anticipate our Non-GAAP effective tax rate landing somewhere in the range of 22% to 24%, and then sitting within the low 20s as we move ahead. That strikes me as the right approach for modeling purposes.

Yatin Suneja analyst
#69

Thanks.

Danielle Brill analyst
#70

Hello, everyone. Good afternoon, and thank you very much for asking, plus congratulations on such a robust quarter. With CRENESSITY, you said there's a bit stronger pull among female pediatric patients, which is what was anticipated, but I'm wondering what further clinical or real-world data is required or could assist in generating wider acceptance among male and adult CAH patients. Apologies if this was covered earlier, yet was there a reason for the Diurnal divestiture, or anything worth inferring from it? Thanks.

Kyle Gano executive
#71

Yes, Kyle Gano here. Let me begin with the Diurnal matter. From where we sit, when we consider the chance that exists in Europe — which is mainly the region where the medicine can be obtained right now — we believed it fit much better with a company that already had additional products on the market at this moment. As our own medicines move forward through the pipeline and reach the commercial stage, we'll look at that possibility, but we thought this was the correct step to take earlier this year. Regarding the other question, Eric Benevich, would you like to handle it?

Eric Benevich executive
#72

Right. So when you look at the various patient groups, it becomes quite apparent that there's strong drive to provide treatment for the pediatric population, and that was evident during the Pediatric Endocrine Society meeting held just last week. The overarching idea there is that for younger individuals, preserving bone age matters, safeguarding the growth trajectory matters, and stopping early onset puberty matters. When it comes to older individuals, meaning adults, the reasons for treating them differ somewhat based on whether they're male or female. Of course, in these adult cases, people worry about bone mineral density, the possibility of heightened cardiovascular risk, mood disorders, and so on. Based on a person's gender and where they are in life, I believe CRENESSITY offers an advantage. Speaking specifically about men — and as a grown man myself, I can attest to this — we aren't great about visiting our physicians regularly, and we tend not to follow through well. What we anticipated from the pre-approval work we conducted was that bringing adult male patients on board would likely require somewhat more time compared with female patients and pediatric patients.

Laura Chico analyst
#73

Hi, I really appreciate you fielding my question. Mine concerns CRENESSITY. Rather than inquiring about how quickly new patients will be added during the rest of 2026 compared with 2025, I'll instead ask what you anticipate regarding compliance and persistence maintenance in this year relative to the prior one. You brought up the bigger sales team. You've likewise observed improvements when it comes to reimbursement. I'm simply attempting to figure out how we ought to consider persistency and compliance figures for CRENESSITY in 2026. Thanks.

Eric Benevich executive
#74

Yes. Thank you, Laura. As you know, over the first twelve months since launch, we have been examining compliance together with persistency, and what we've found is that it holds quite steady no matter when a patient began therapy — early in the prior year, midway through it, or even late in that same year. It has remained extremely steady. In my view, two factors are really behind this. The first is the truly excellent tolerability profile for CRENESSITY that showed up in the clinical trials as well as the open-label extension; the second is that a single pharmacy distributor handles our product, namely PANTHERx Rare, and they excel at contacting patients and doing follow-up with them. They've achieved considerable success when a refill becomes due, managing to get in touch with that patient and secure authorization.

Sam Huang analyst
#75

Hello, I'm Sam Huang, filling in for David. I appreciate the chance to ask something. This is a brief question regarding crinecerfont and CAH patients younger than 4 years old, the phase II study. For this subset of patients, how ought we to view the opportunity — maybe regarding how many patients there are, the unmet need, or what it might add to the current CAH franchise later on? And if you have anything more to share about the regulatory or commercial timeline for this development, that would help. Thanks.

Eric Benevich executive
#76

I'll take the unmet need portion. As I mentioned, with these younger patients, it's clear that intervening sooner is preferable when it comes to safeguarding the growth trajectory, bone age, and similar factors. At present, the labeling covers only patients aged 4 and older. A fair number of inquiries have come to us from parents whose children are below 4, asking whether treatment is available or if they could obtain it, and definitely from their pediatric endocrinologist as well. We understand an unmet need exists in that group, and we would like to be in a position to address it.

Sanjay Keswani executive
#77

Yes, when it comes to the regulatory pathway, we obviously require data from patients under 4 years old. That is the primary reason we are launching this study here in the U.S. As for timing, our assumption is that within the coming 2 years, we will have gathered the data needed to potentially broaden the label.

Sam Huang analyst
#78

Great, thanks.

Rudy Lee analyst
#79

Thanks for taking my question, and congratulations once more on the strong quarter. I just have a follow-up about INGREZZA. I believe we already touched on seasonality, but could you give us more color on what the pattern looks like for the remaining three quarters, particularly since the first quarter was relatively stronger than in prior years? Did you observe any shifts in market dynamics related to the IRA negotiation for Raftio? Thanks.

Eric Benevich executive
#80

On the whole, we expect 2026 to resemble earlier years quite closely, with seasonal payer disruption showing up during Q1, largely involving Medicare patients who require reauthorization as well as commercial patients whose out-of-pocket copay is reset. Fortunately, we've already gotten past that part of the year. This year we also had an expansion underway. I'd note that our team did a truly outstanding job keeping momentum behind our business and growing our field sales organization. That took effect in early Q2. Typically, once that Q1 payer seasonality passes, what we observe is a very strong emphasis on execution, on driving new patient starts via screening initiatives throughout the rest of the year. This year especially, with a larger field sales team, as I said in my prepared remarks, we anticipate seeing real lift and benefit from that bigger team as we move into the later portion of the year.

Rudy Lee analyst
#81

Understood. That's quite useful. Thank you.

Analyst analyst
#82

Hi there, Malcolm filling in for Evan. Appreciate you fielding our question. Congratulations on the quarter. To circle back on the persistence and compliance figures for CRENESSITY — I realize you mentioned these have stayed quite robust and steady from the time of launch. Regarding the small number of discontinuations that do happen, would you say those are primarily tied to insurance matters or to the product profile, and has that shifted at all across the first year? Thank you.

Eric Benevich executive
#83

Yes; it's tough to say much about what has ended up being a very small share of patients stopping treatment. Broadly speaking, I'd note that we have not observed patients halting because of insurance. As a matter of fact, out-of-pocket expenses are quite minimal; they come in under $10 per patient each month, and a large number of patients pay nothing whatsoever. Affordability has not truly been a problem or a cause for stopping. There have been cases in which patients relocated or were lost to follow-up — those are extremely rare. Without question, we have felt very good about the persistency observed roughly 5 quarters into this launch.

Analyst analyst
#84

Got it, thank you.

Kyle Gano executive
#85

Thanks, Nikki, and I appreciate all of you being on today's call, for your ongoing interest in and backing of Neurocrine. The robust beginning to this year has been really heartening for us. It provides considerable momentum as we look at the quarters still ahead, and similarly, the momentum we keep building throughout our commercial portfolio, along with strides made in moving our clinical pipeline forward; we're eagerly anticipating meeting with all of you at the investor conferences and events coming up. Thanks once more, and we'll be in touch before long.

Operator operator
#86

Thanks a lot; that wraps up the call for today. We're grateful you took the time to join and take part. You're welcome to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Neurocrine Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Neurocrine Biosciences, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.